A5039499448- Glioma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Psychosomatic Disorders and Their Treatments
- Neuroblastoma Research and Treatments
- Ocular Oncology and Treatments
- Cancer, Hypoxia, and Metabolism
- Mental Health Research Topics
- RNA regulation and disease
- Sex and Gender in Healthcare
- Functional Brain Connectivity Studies
- Cancer-related cognitive impairment studies
- TGF-β signaling in diseases
- Mathematical Biology Tumor Growth
- Medical Imaging and Analysis
- Neurological disorders and treatments
- Brain Metastases and Treatment
- Connective tissue disorders research
- Multiple Sclerosis Research Studies
- Histone Deacetylase Inhibitors Research
- Complementary and Alternative Medicine Studies
- Mental Health Treatment and Access
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
Harvard University
2018-2025
Massachusetts General Hospital
2019-2025
Dana-Farber Cancer Institute
2024-2025
Center for Neuro-Oncology
2024-2025
Brigham and Women's Hospital
2022-2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
2018
Abstract Background Patients with glioblastoma experience high physical and psychosocial symptom burden. Poor social relationships have been shown to increase the risk of neurologic illnesses decline, conversely, strong personal networks (PSN) reduce mortality improve quality life. The aim this pilot study is determine feasibility measuring PSN in patients. Methods We recruited 25 adult patients between initial diagnosis first cycle adjuvant chemotherapy from March September 2023 outpatient...
Artificial intelligence (AI) describes the application of computer algorithms to solution problems that have traditionally required human intelligence. Although formal work in AI has been slowly advancing for almost 70 years, developments last decade, and particularly year, led an explosion applications multiple fields. Neuro-oncology not escaped this trend. Given expected integration AI-based methods neuro-oncology practice over coming we set provide overview existing technologies as they...
Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of trials remains undefined. This study describes the real-world utilization mutant IDH1 inhibitor (IDHi), ivosidenib, patients with glioma. We retrospectively reviewed and radiographic data from treated ivosidenib monotherapy 2020 to 2024 at Dana-Farber Cancer Institute Massachusetts General Hospital. cohort included 74...
An elderly woman presented with subacute onset of chorea following a hospitalization for severe, uncontrolled diabetes, urinary tract infection, and 6 months depression. Her neurological examination demonstrated bilateral involving the arms, legs, jaw. MRI brain T1 hyperintensity. She was diagnosed diabetic striatopathy, also known as nonketotic hyperglycemic chorea, rare complication diabetes mellitus that classically causes hemichorea in setting very high blood glucose without ketosis....
Abstract BACKGROUND Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel therapeutic strategy for treating IDHm glioma, though their optimal use outside of clinical trials remains undefined. This study describes real world utilization the IDH1 inhibitor, ivosidenib, in patients with glioma. METHODS We retrospectively reviewed and radiographic data from glioma treated ivosidenib monotherapy at Dana-Farber Cancer Institute Massachusetts General Hospital 2020-2024. Patients...
Abstract BACKGROUND Astrocytoma, IDH-mutant, WHO grade 4, are classified as a separate entity in the 2021 classification of central nervous system tumors and have been poorly characterized literature. In this study, we report on clinical outcomes large cohort newly diagnosed 4 IDH-mutant astrocytoma. METHODS We retrospectively identified adult patients with astrocytoma, treated for their initial diagnosis at Dana-Farber Cancer Institute Massachusetts General Hospital between 2010 2021....
Abstract BACKGROUND In patients with glioblastoma, the predicted progressive deterioration in physical and cognitive abilities leads to decreased quality of life for their caregivers. Research has shown that one’s social environment is a major contributor health outcomes. However, this population, study gap literature. METHODS We examined personal networks 25 adult glioblastoma at one time between initial diagnosis first cycle adjuvant chemotherapy from March September 2023. additionally...
Although rare, the co-occurrence of multiple sclerosis (MS) and glioma poses unique challenges in terms diagnosis management for both neurologists neuro-oncologists.Here we report on a single-center cohort four patients with who developed gliomas.Our reflects epidemiology relative frequency IDH-wildtype IDH-mutant cases. The 3 out 4 cases presented did not develop their tumors areas pre-existing demyelinating lesions.We find evidence to support hypothesis that chronic gliosis from plaques...
Brachial plexopathy is a common consideration in the differential diagnosis of upper extremity sensory and motor deficits, neoplasms signify one possible etiology brachial plexopathy. Of neoplastic plexopathies, hemangiomas involving plexus are rare. Most reported cases describe extraneural that present as palpable, tender neck mass associated with pain disturbance, minimal deficits. Here we share case 48 year-old man intraneural epithelioid hemangioma who presented prominent weakness no...
<p>Supplementary Figure S1. p15, p16, and Ki-67 expression in a benign BRAF(V600E) nevus. Supplementary S2. Active CDK4 reverses BRAF(V600E)-mediated melanocyte growth arrest. S3. BRAF(V600E), p16 normal nevus MCs. S4. Engineered p15 melanocytes. S5. Effects of shRNA rescue lentiCRISPRCAS9 mediated loss diBRAF(V600E) S6. Loss CDKN2A CDKN2B promotes proliferation Melanocytes. S7. Expression Benign Nevi Melanoma. S8. Nevus with Adjacent S9. Erk 1/2 Target EGR-1 is Upregulated BRAFV600E...
<div>Abstract<p>Deletion of the entire <i>CDKN2B–CDKN2A</i> gene cluster is among most common genetic events in cancer. The tumor-promoting effects are generally attributed to loss <i>CDKN2A</i>-encoded p16 and p14ARF tumor suppressors. degree which associated <i>CDKN2B</i>-encoded p15 contributes human tumorigenesis unclear. Here, we show that <i>CDKN2B</i> highly upregulated benign melanocytic nevi, maintaining nevus melanocytes a...
<div>Abstract<p>Deletion of the entire <i>CDKN2B–CDKN2A</i> gene cluster is among most common genetic events in cancer. The tumor-promoting effects are generally attributed to loss <i>CDKN2A</i>-encoded p16 and p14ARF tumor suppressors. degree which associated <i>CDKN2B</i>-encoded p15 contributes human tumorigenesis unclear. Here, we show that <i>CDKN2B</i> highly upregulated benign melanocytic nevi, maintaining nevus melanocytes a...
<p>Supplementary Figure S1. p15, p16, and Ki-67 expression in a benign BRAF(V600E) nevus. Supplementary S2. Active CDK4 reverses BRAF(V600E)-mediated melanocyte growth arrest. S3. BRAF(V600E), p16 normal nevus MCs. S4. Engineered p15 melanocytes. S5. Effects of shRNA rescue lentiCRISPRCAS9 mediated loss diBRAF(V600E) S6. Loss CDKN2A CDKN2B promotes proliferation Melanocytes. S7. Expression Benign Nevi Melanoma. S8. Nevus with Adjacent S9. Erk 1/2 Target EGR-1 is Upregulated BRAFV600E...